Mutations associated with HNPCC predisposition – Update of ICG-HNPCC/INSiGHT mutation database

Päivi Peltomäki\textsuperscript{a,*} and Hans Vasen\textsuperscript{b}
\textsuperscript{a}Department of Medical Genetics, University of Helsinki, Helsinki, Finland
\textsuperscript{b}The Netherlands Foundation for the Detection of Hereditary Tumours and Department of Gastroenterology, Leiden University Medical Centre, The Netherlands

Abstract. In 1994, the International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer (ICG-HNPCC) established an international database of mutations identified in families with Lynch (HNPCC) syndrome. The data are publicly available at http://www.nfdht.nl. The information stored in the database was systematically analyzed in 1997, and at that time, 126 different predisposing mutations were reported affecting the DNA mismatch repair genes MSH2 and MLH1 and occurring in 202 families. In 2003, the ICG-HNPCC and the Leeds Castle Polyposis Group (LCPG) merged into a new group, INSiGHT (International Society for Gastrointestinal Hereditary Tumors). The present update of the database of DNA mismatch repair gene mutations of INSiGHT includes 448 mutations that primarily involve MLH1 (50%), MSH2 (39%), and MSH6 (7%) and occur in 748 families from different parts of the world.

Keywords: Hereditary nonpolyposis colorectal cancer, MLH1, MLH3, MSH2, MSH6, PMS1, PMS2

1. Introduction

Hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) is a multi-organ cancer syndrome that is associated with heritable defects in DNA mismatch repair (MMR). Mutations in four MMR genes, MSH2, MLH1, MSH6, and PMS2, have been convincingly linked to HNPCC susceptibility (Table 1). Two further genes, MLH3 and PMS1, have also been implicated in HNPCC predisposition, but their roles are less clear. Germline mutations in MMR genes give rise to characteristic clinical phenotypes, including a defined spectrum of cancers that show microsatellite instability (MSI) as a manifestation of MMR deficiency [22]. Apart from MMR genes, HNPCC-like phentypes in occasional families may be due to germline mutations in a variety of other genes, including the APC gene variants I1307K and E1317Q [9], TGF/RII [21], CHD1 [30], EXO1 [44], and MYH [2]. With rare exceptions (EXO1), tumors from such families do not display MSI. As HNPCC is traditionally viewed as a MMR deficiency syndrome, the latter genes are not included in the present review or in the mutation database.

Information of mutations and polymorphisms detected in the MMR genes listed in Table 1 are available in the database maintained by the previous International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer (ICG-HNPCC), current INSiGHT. Since the establishment of the database in 1994, the data deposited in it (available at http://www.nfdht.nl) have steadily increased from 126 mutations in the original report [28] to 448 mutations at present. Individual investigators have contributed most of the information (an electronic mutation submission form is available at the Internet address given above); the rest has been retrieved from published literature reports. While a ma-
Table 1
HNPCC-associated human MMR genes

| Gene | Chromosomal location | No. of exons |
|------|----------------------|--------------|
| MSH2 | 2p21                 | 16           |
| MLH1 | 3p21-23              | 19           |
| MSH6 | 2p21                 | 10           |
| PMS2 | 7p22                 | 15           |
| MLH3 | 14q24.3              | 12           |
| PMS1 | 2q31-q33             | Not determined |

Table 2
Number of mutations considered pathogenic that have been deposited in the ICG-HNPCC/INSiGHT mutation database (http://www.nfdht.nl) as of July 31st, 2003

| Gene | Number of mutations (%) |
|------|-------------------------|
| MSH2 | 175 (39%)               |
| MLH1 | 225 (50%)               |
| MSH6 | 32 (7%)                 |
| PMS2 | 5 (1%)                  |
| MLH3 | 16 (3%)                 |
| PMS1 | 1 (< 1%)                |
| Total| 448 (100%)              |

The 448 MMR gene alterations detected in the germline to date occur in 748 families from different parts of the world (Table 3). While most MSH2- and MLH1-associated families meet the stringent Amsterdam I criteria for HNPCC, mutations in the remaining genes are mainly associated with Amsterdam I-negative families.

In addition to sequence changes considered pathogenic, the database also contains information of apparently nonpathogenic sequence variants and polymorphisms. Emphasis is given on those variants for which allele frequencies in the population have been determined. The database currently lists 108 nonpathogenic alterations (28 for MSH2, 27 for MLH1, 43 for MSH6, 5 for PMS2, and 5 for MLH3).

It may be difficult to determine the pathogenicity of missense and in-frame alterations as well as some splice changes. A few changes have been reported both as pathogenic mutations and as innocuous sequence variants to the database (G322D in MSH2, and V326A and K618A in MLH1). For missense mutations, the most important theoretical criteria in support of pathogenicity include nonconservative nature of the amino acid change, evolutionary conservation of the amino acid, absence in the normal population, cosegregation with disease, and association with MSI or lack of specific protein in tumor tissue. Most missense mutations of MSH2 and MLH1 meet one or several of these criteria.

For mutations for which functional data are available [6, 11, 12, 16, 27, 31, 33] there is generally a good agreement between theoretical predictions and functional classification.

2. Mutations and polymorphisms

As of July 31, 2003 the database contains information of 448 germline alterations that are likely to be pathogenic and are referred to as mutations (Table 2). Of these, 50% affect MLH1, 39% MSH2, and 7% MSH6, while the share of the remaining genes is less than 5%. According to available reports, germline mutations in PMS2 are rare in classical HNPCC families [20] and are primarily associated with the Turcot syndrome variant [4,14,23].

The role of MLH3 as an HNPCC susceptibility gene relies on two population-based reports, one based on Dutch [45] and the other one on Swedish [19] HNPCC or colon cancer families. Among a total of 16 germline variants that were absent in the normal population, only 2 were frameshift mutations, whereas the remaining ones were of the missense type with uncertain pathogenic significance. Moreover, while some MLH3 mutations showed co-segregation with disease in the families studied, others did not [19].

More data are clearly needed for a reliable evaluation of the significance of MLH3 in HNPCC predisposition. Finally, a single PMS1 germline mutation has been reported [25], a nonsense mutation occurring in a patient with colon and other cancers from a family meeting the Amsterdam I criteria for HNPCC [34]. However, re-examination of the same family revealed an additional mutation in MSH2 (large deletion encompassing exons 1–7), and only the MSH2 mutation co-segregated with colon cancer [20]. Thus, there is presently no convincing evidence that germline mutation of PMS1 causes predisposition to HNPCC-type cancers; however, a possible role of PMS1 as a susceptibility gene for some other cancers cannot be excluded [20].

It may be difficult to determine the pathogenicity of missense and in-frame alterations as well as some splice changes. A few changes have been reported both as pathogenic mutations and as innocuous sequence variants to the database (G322D in MSH2, and V326A and K618A in MLH1). For missense mutations, the most important theoretical criteria in support of pathogenicity include nonconservative nature of the amino acid change, evolutionary conservation of the amino acid, absence in the normal population, cosegregation with disease, and association with MSI or lack of specific protein in tumor tissue. Most missense mutations of MSH2 and MLH1 meet one or several of these criteria.

For mutations for which functional data are available [6, 11, 12, 16, 27, 31, 33] there is generally a good agreement between theoretical predictions and functional classification.
Table 3

Fulfilment (+ or −) of Amsterdam I criteria among families associated with MMR gene mutations

| Gene   | Amsterdam I+ | Amsterdam I− | Not specified | Total (%) |
|--------|--------------|--------------|---------------|-----------|
| MSH2   | 143          | 92           | 50            | 285 (38%) |
| MLH1   | 253          | 71           | 77            | 401 (54%) |
| MSH6   | 7            | 26           | 4             | 37 (5%)   |
| PMS2   | 1            | 4            | 0             | 5 (< 1%)  |
| MLH3   | 0            | 19           | 0             | 19 (3%)   |
| PMS1   | 1            | 0            | 0             | 1 (< 1%)  |
| Total  | 405 (54%)    | 212 (28%)    | 131 (18%)     | 748 (100%)|

3. Sites and types of mutation

The exonic distribution of germline mutations along the MSH2, MLH1, and MSH6 genes is shown in Fig. 1. As a rule, the mutations are scattered throughout the genes, with some hot spot areas in exons 12 and 3 for MSH2, exons 16 and 1 for MLH1, and exon 4 (the largest exon) for MSH6. Apart from exons and intron/exon borders, a few point mutations have been identified in the promoter regions of MSH2 [32] and MLH1 [10], and at least for some, functional data are available to support their pathogenicity.

A majority of HNPCC-associated MMR gene alterations are frameshift or nonsense mutations that lead to truncated proteins (Fig. 2). For MLH1 and MSH6, missense mutations are also common constituting more than one-third of all mutations in these genes. Most alterations observed in MLH3 in HNPCC- or HNPCC-like families are of the missense type. Pathogenicity of HNPCC-associated mutations typically results from the loss of important interaction domains (truncating mutations) or changes in the local structure or conformation (missense mutations) that impair the ability of the proteins to interact with their partners or other components of the MMR pathway, or otherwise properly accomplish MMR or other functions these proteins are responsible for [7,15].

Yet, the overall share of the three most common MSH2 and MLH1 mutations, if counted together, is only 13% of all mutation-positive families (95/748).

Typically, recurrent mutations arise de novo in different background haplotypes. However, some are associated with shared haplotypes between different families suggesting a common ancestral origin (founder mutations). Founding mutations are characteristic of isolated populations, such as the Ashkenazi Jews or Finns, and provide important targets for mutation diagnostics in these particular populations. Thus, a missense mutation (G>C at nucleotide 1906 in exon 12 of MSH2, designated as A636P) accounts for one-third of HNPCC in Ashkenazi Jewish families that fulfil the Amsterdam criteria I [34] or II [37]; it is infrequent or absent in other populations [8]. Similarly, two founding mutations in MLH1, a 3.5-kb genomic deletion affecting exon 16 (“Mutation 1”) and a splice acceptor site mutation (g>a at 454-1) of exon 6 (“Mutation 2”), together account for 63% of all mutations identified in Finnish HNPCC families [24,26]. So far, neither of these two mutations has been shown to occur in families of non-Finnish origin. Recently, a genomic deletion encompassing MSH2 exons 1–6 was found to represent a founder mutation among North American kindreds, accounting for 10% of the studied cohort [39]. In analogy to the Finnish MLH1 “Mutation 1”, breakpoint analysis suggested the origin of the MSH2 deletion as a result of Alu-mediated recombination. Finally, some mutations may arise de novo in some populations and represent founding mutations in others. For example, the recurrent MSH2 intron 5 splice site mutation (Table 4) has multiple origins based on haplotype analysis with MSH2-linked markers, but is a founding mutation in Newfoundland, Canada [5].

4. Unique vs. recurrent mutations and the role of ethnicity

Most mutations reported to the database (362/448, 81%) are unique, i.e. specific to each family. This observation together with the fact that the mutations are distributed throughout the genes (see above) means that for the detection of a predisposing mutation in a new family, the entire genes generally need to be screened. However, a few recurrent mutations are known that occur in HNPCC families all over the world (Table 4).
(often referred to as “major” MMR genes) especially in families that meet the Amsterdam criteria, and mutations in these genes or MSH6 in families that do not meet these criteria (Table 3). In the Muir-Torre variant, which is characterized by the occurrence of sebaceous gland tumors together with HNPCC-type malignancy, MSH2 is primarily affected (ref. 18 and http://www.nfdht.nl). The genetic basis of Turcot syndrome (featured by the coexistence of primary brain tumor and colorectal adenoma or carcinoma) is heterogeneous and involves the MMR genes MLH1 and PMS2 or the APC gene (ref. 14 and http://www.nfdht.nl).

Consistent with the observed vertical transmission of cancer susceptibility in HNPCC families (autosomal dominant inheritance), one copy of a MMR gene is mutant and the other one wild type in the germline of any
individual who has inherited the susceptibility. Rare instances of homozygosity [29,38,40,41] or compound heterozygosity [4,13] for MMR gene mutations have been described. Homozygosity for MLH1 or MSH2 mutations is associated with atypical tumor spectrum (hematological malignancy and neurofibromatosis type 1) as well as constitutional mutator phenotype. An individual heterozygous for two missense mutations in MLH1 developed breast cancer at age 35 combined with constitutional mutator phenotype, but showed no colon cancer at the time of the latest observation (45 years) [13]. Another individual heterozygous for two truncating PMS2 mutations had a Turcot phenotype and microsatellite instability in both normal and tumor tissue [4]. Remarkably, the parents, who both carried one PMS2 mutation, were clinically unaffected, suggesting recessive inheritance in this exceptional case.

Table 5 summarizes the characteristic clinical features and MSI status associated with mutations in the different MMR genes. Families with MSH2 or MLH1 mutations mainly display typical HNPCC and high-degree of MSI in tumors (for “grading” of MSI, see ref. 3). Furthermore, compared to carriers of MLH1 mutations, MSH2 mutation carriers appear to be at higher risk for extracolonic cancers [36] and their lifetime risk of developing any cancer may be higher [35]. MSH6 mutations are often associated with atypical HNPCC (characterized by small family size, atypical tumor spectrum, late age at onset, and reduced penetrance) with high- or low-degree MSI in tumors [1,17,42,43]. Moreover, families with MSH6 mutations have a higher risk of developing endometrial cancer than families with MSH2 or MLH1 mutations [42]. Carriers of PMS2 mutations usually show features of Turcot syndrome and – as mentioned [4] – the penetrance of mutations may vary. Finally, as a rule, families with MLH3 mutations do not fulfil the Amsterdam criteria,
Table 4
The most common recurrent mutations that occur in HNPCC families worldwide (irrespective of ethnic origin)

| Mutation | Consequence | No. of associated families |
|----------|-------------|---------------------------|
| MSH2    | a>t at nt. 942 + 3 (intron 5) | Deletion of exon 5 (in frame) | 42 |
|         | Del AAT at nt. 1786, codon 596 (exon 12) | Deletion of an amino acid (Asn) (in frame) | 8 |
|         | C>T at nt. 2038, codon 680 (exon 13) | Arg>stop (nonsense) | 7 |
| MLH1    | Del AAG at nt. 1846, codon 616 (exon 16) | Deletion of an amino acid (Lys) (in frame) | 20 |
|         | C>T at nt. 350, codon 117 (exon 4) | Thr>Met (missense) | 10 |
|         | AA>GC at nt. 1852, codon 618 (exon 16) | Lys>Ala missense | 8 |

Table 5
Clinical and MSI phenotypes associated with germline mutations in MMR genes

| Gene    | Clinical phenotype                                                                 | MSI phenotype                        |
|---------|------------------------------------------------------------------------------------|-------------------------------------|
| MSH2    | Mostly typical HNPCC, also a major Muir-Torre gene.                                | MSI-High                            |
| MLH1    | Mostly typical HNPCC.                                                              | MSI-High                            |
| MSH6    | Typical (minority) or atypical HNPCC (majority) with frequent endometrial cancers. | MSI-High or MSI-Low                 |
| PMS2    | Turcot syndrome.                                                                  | MSI-High                            |
| MLH3    | Atypical HNPCC.                                                                   | Variable (from MSI-High to no MSI)  |

6. Conclusion

During its almost a decade of existence, the ICG-HNPCC/INSiGHT mutation database has established its position as an important repository of information for both clinicians and researchers. Knowledge of mutations predisposing to HNPCC provides the basis for studies of mutation mechanisms and consequences, the design of diagnostic strategies, and increased understanding of genotype-phenotype correlations.

Acknowledgments

The authors thank all investigators who have submitted information of mutations and polymorphisms to the database. Mary Velthuizen is thanked for data management. This work was supported by the Sigrid Juselius Foundation, the Academy of Finland, the Finnish Cancer Foundation, and the NIH (grant CA82282).

References

[1] Y. Akiyama, H. Sato, T. Yamada, H. Nagasaki, A. Tsuchiya, R. Abe and Y. Yuasa, Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred, Cancer Research 57 (1997), 3920–3923.

[2] N. Al-Tassan, N.H. Chmiel, J. Maynard, N. Fleming, A.L. Livingston, G.T. Williams, A.K. Hodges, D.R. Davies, S.S. David, J.R. Sampson and J.P. Cheadle, Inherited variants of MYH associated with somatic G:C to T:A mutations in colorectal tumors, Nature Genetics 30 (2002), 227–232.

[3] C.R. Boland, S.N. Thibodeau, S.R. Hamilton, D. Sidransky, J.R. Eshleman, R.W. Burt, S.J. Meltzer, M.A. Rodriguez-Bigas, R. Fodde, G.N. Ranzani and S. Srivastava, A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer, Cancer Research 58 (1998), 5248–5257.

[4] M. De Rosa, C. Fasano, L. Panariello, M.I. Scarano, G. Belli, A. Iannelli, F. Ciciliano and P. Izzo, Evidence for a recessive inheritance of Turcot’s syndrome caused by compound heterozygous mutations within the PMS2 gene, Oncogene 19 (2000), 1719–1723.

[5] D.C. Desai, J.C. Lockman, R.B. Chadwick, X. Gao, A. Percepe, D.G.R. Evans, M. Miyaki, S.T. Yuen, P. Radice, E.R. Maher, F.A. Wright and A. de la Chapelle, Recurrent germline mutation in MSH2 arises frequently de novo, Journal of Medical Genetics 37 (2000), 646–652.

[6] A.R. Ellison, J. Lofing and G.A. Bitter, Functional analysis of human MLH1 and MSH2 missense variants and hybrid human-yeast MLH1 proteins in Saccharomyces cerevisiae, Human Molecular Genetics 10 (2001), 1889–1900.

[7] R. Fishel, The selection for mismatch repair defects in hereditary nonpolyposis colorectal cancer: revising the mutator hypothesis, Cancer Research 61 (2001), 7369–7374.

[8] W.D. Foxlkes, I. Thiffault, S.B. Gruber, M. Horwitz, N. Hamel, C. Lee, J. Shia, A. Markowitz, A. Figer, E. Friedman, D. Farber, C.M.T. Greenwood, J.D. Bonner, K. Nafa, T. Walsh, V. Marcus, L. Tomsho, J. Gebert, F.A. Macrae, C.L. Gaff, B. Bressac-de Pallerets, P.K. Gregersen, J.N. Weitzel, P.H. Gordon, E. MacNamara, M.-C. King, H. Hampe, A. de la Chapelle, J. Boyd, K. Offit, G. Rennert, G. Chong and N.A. Ellis, The founder mutation MSH2*1906G>C is an impor-
tient cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population. American Journal of Human Genetics 71 (2002), 1395–1412.

[9] I.M. Frayling, N.E. Beck, M. Ilyas, I. Dove-Edwin, P. Good- man, K. Pack, J.A. Bell, C.B. Williams, S.V. Hodgson, H.J.W. Thomas, I.C. Talbot, W.F. Bodmer and I.P.M. Tomlinson, The APC variants H139T and E1317Q are associated with colo- rectal tumors, but not always with a family history, Proceedings of the National Academy of Sciences USA 95 (1998), 10722–10727.

[10] R.C. Green, A.G. Green, M. Simms, A. Pater and J.S. Green, Germline hMLH1 promoter mutation in a Newfoundland HNP- CCC kindred. Clinical Genetics 64 (2003), 220–227.

[11] S. Guerreuret, S. Acharya and R. Fishel, The interaction of the human MutL homologues in hereditary nonpolyposis colon cancer, Journal of Biological Chemistry 274 (1999), 6336–6341.

[12] S. Guerreuret, T. Wilson, S. Gradia and R. Fishel, Interactions of human hMSH2 with hMSH1 and hMSH2 with hMSH6: examination of mutations found in hereditary nonpolyposis colorectal cancer, Molecular and Cellular Biology 18 (1998), 6616–6623.

[13] P. Hackman, P. Tannergård, S. Osei-Mensa, J. Chen, M.F. Kane, R. Kolodner, B. Lambert, D. Hellgren and A. Lindblom, A human compound heterozygote for two MLH1 missense mutations, Nature Genetics 17 (1997), 135–136.

[14] S.R. Hamilton, B. Liu, R.E. Parsons, N. Papadopoulos, J. Jen, J. Jiricny and M. Nyström-Lahti, Mismatch repair defects in the Ashkenazi Jewish population, tant cause of hereditary nonpolyposis colorectal cancer in the

[15] M. Nyström-Lahti, P. Kristo, N.C. Nicolaides, S.-Y. Chang, L.A. Aaltonen, A.-L. Moisio, H.J. Järvinen, J.-P. Mecklin, K.W. Knudtzen, B. Vogelstein, A. de la Chapelle and P. Pel- tomäki, Founding mutations and Alu-mediated recombination in hereditary colon cancer, Nature Medicine 1 (1995), 1203–1206.

[16] M. Nyström-Lahti, C. Perrera, M. Raschle, E. Panyushkina-Seiler, G. Marra, A. Curci, B. Quaresima, F. Costanzo, M. D’Urso, S. Venuta and J. Jiricny, Functional analysis of MLH1 mutations linked to hereditary nonpolyposis colon cancer, Genes Chromosomes and Cancer 33 (2002), 160–167.

[17] P. Peltonäkii and H.F. Vasen, Mutations predisposing to hered- itary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer, Gastroenterolo- gy 113 (1997), 1146–1158.

[18] M.D. Ricciardone, T. Ozcelik, B. Cevher, H. Özdag, M. Tuncer, A. Gürgey, Ö. Uzunalimoglu, H. Çetinkaya, A. Tanyeli, E. Erken and M. Öztürk, Human MLH1 deficiency predisposes to hematological malignancy and neurofibromato- sis type 1, Cancer Research 59 (1999), 290–293.

[19] F.M. Richards, S.A. McKee, M.H. Rajpar, T.R.P. Cole, D.G.R. Cove, G. Marra, A. Curci, B. Quaresima, F. Costanzo, M. D’Urso, S. Venuta and J. Jiricny, Functional analysis of MLH1 mutations linked to hereditary nonpolyposis colon cancer, Genes Chromosomes and Cancer 33 (2002), 160–167.

[20] H.T. Lynch and A. de la Chapelle, Genetic susceptibility to non-polyposis colorectal cancer, Journal of Medical Genetics 36 (1999), 801–818.

[21] M. Miyaki, J. Nishio, M. Konishi, R. Kikuchi-Yanoshita, K. Tanaka, M. Muraoaka, M. Nagato, J.-M. Chong, M. Koike, T. Terada, Y. Kawahara, A. Fukutome, J. Tomiyama, Y. Chuganji, M. Momos and J. Usunomiyia, Drastic genetic instability of tumors and normal tissues in Turcot syndrome, Oncogene 15 (1997), 2877–2881.

[22] A.-L. Moisio, P. Sistonen, J. Weissenbch, A. de la Chapelle and P. Peltonäkii, Age and origin of two common MLH1 mutations predisposing to hereditary colon cancer, American Journal of Human Genetics 59 (1996), 1243–1251.

[23] N.C. Nicolaides, N. Papadopoulos, B. Liu, Y.-F. Wei, K.C. Carter, S.M. Ruben, C.A. Rosen, W.A. Haseltine, R.D. Fleischmann, C.M. Fraser, M.D. Adams, J.C. Venter, M.G. Dunlop, S.R. Hamilton, G.M. Petersen, A. de la Chapelle, B. Vogel- stin and K.W. Knudtzen, Mutations in two PMS homologues in hereditary nonpolyposis colorectal cancer, Nature 371 (1994), 75–80.

[24] M. Nyström-Lahti, P. Kristo, N.C. Nicolaides, S.-Y. Chang, L.A. Aaltonen, A.-L. Moisio, H.J. Järvinen, J.-P. Mecklin, K.W. Knudtzen, B. Vogelstein, A. de la Chapelle and P. Pel- tomäki, Founding mutations and Alu-mediated recombination in hereditary colon cancer, Nature Medicine 1 (1995), 1203–1206.

[25] M. Nyström-Lahti, C. Perrera, M. Raschle, E. Panyushkina-Seiler, G. Marra, A. Curci, B. Quaresima, F. Costanzo, M. D’Urso, S. Venuta and J. Jiricny, Functional analysis of MLH1 mutations linked to hereditary nonpolyposis colon cancer, Genes Chromosomes and Cancer 33 (2002), 160–167.

[26] P. Peltonäkii and H.F. Vasen, Mutations predisposing to hered- itary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer, Gastroentero- gy 113 (1997), 1146–1158.

[27] H. Shimodaira, N. Filosi, H. Shibata, T. Suzuki, P. Radice, R. Kanamarru, S.H. Friend, R.D. Kolodner and C. Ishioka, Func- tional analysis of human MLH1 mutations in Saccharomyces cerevisiae, Nature Genetics 19 (1998), 384–389.

[28] K.H. Shin, J.H. Shin, J.H. Kim and J.G. Park, Mutational analysis of promoters of mismatch repair genes hMSH2 and hMLH1 in hereditary nonpolyposis colorectal cancer and early onset colorectal cancer patients: identification of three novel germ-line mutations in promoter of the hMSH2 gene, Cancer Research 62 (2002), 38–42.

[29] J. Trojan, S. Zuezem, A. Randolph, C. Hemmerle, A. Brieger, J. Raedle, G. Plotz, J. Jiricny and G. Marra, Functional analysis of hMLH1 variants and HNPCC-related mutations using a human expression system, Gastroenterology 122 (2002), 211–219.

[30] H.F.A. Vasen, J.-P. Mecklin, P.M. Khan and H.T. Lynch, The International Collaborative Group on Hereditary Non-
Polyposis Colorectal Cancer (ICG-HNPCC), *Dis Colon Rectum* **34** (1991), 424–425.

[35] H.F.A. Vasen, A. Stormorken, F.H. Menko, F.M. Nagengast, J.H. Kleibeuker, G. Griffioen, B.G. Taal, P. Møller and J.T. Wijnen, MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families, *Journal of Clinical Oncology* **19** (2001), 4074–4080.

[36] H.F.A. Vasen, J.T. Wijnen, F.H. Menko, J.H. Kleibeuker, B.G. Taal, G. Griffioen, F.M. Nagengast, E.J. Meijers-Heijboer, L. Bertario, L. Varesco, M. Bisgaard, J. Mohr, R. Fodde and P. Meera Khan, Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis, *Gastroenterology* **110** (1996), 1020–1027.

[37] H.F. Vasen, P. Watson, J.-P. Mecklin and H.T. Lynch, New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC, *Gastroenterology* **111** (1999), 1453–1456.

[38] S. Vilkki, J.-L. Tsao, A. Loukola, M. Pöyhönen, O. Vierimaa, R. Herva, L.A. Aaltonen and D. Shibata, Extensive somatic microsatellite mutations in normal human tissue, *Cancer Research* **61** (2001), 4541–4544.

[39] A. Wagner, A. Barrows, J.Th. Wijnen, H. van der Klift, P.F. Franken, P. Verkuijlen, H. Nakagawa, M. Geugjen, S. Jadhmo-H-Changur, C. Breukel, H. Meijers-Heijboer, H. Morreau, M. van Puijenbroek, J. Burn, S. Coronel, Y. Kinariski, R. Okimoto, P. Watson, J. F. Lynch, A. de la Chapelle, H.T. Lynch and R. Fodde, Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: High mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene, *American Journal of Human Genetics* **72** (2003), 1088–1100.

[40] Q. Wang, C. Lasset, F. Desseigne, D. Frappaz, C. Bergeron, C. Navarro, E. Ruano and A. Puisieux, Neurofibromatosis and early onset of cancers in hMLH1-deficient children, *Cancer Research* **59** (1999), 294–297.

[41] D. Whiteside, R. McLeod, G. Graham, J.L. Steckley, K. Booth, M.J. Somerville and S.E. Andrew, A homozygous germ-line mutation in the human MSH2 gene predisposes to hematological malignancy and multiple cafe-au-lait spots, *Cancer Research* **62** (2002), 359–362.

[42] J. Wijnen, W. de Leeuw, H. Vasen, H. van der Klift, P. Møller, A. Stormorken, H. Meijers-Heijboer, D. Lindhout, F. Menko, S. Vossen, G. Möslin, C. Tops, A. Bröcker-Vriends, Y. Wu, R. Hofstra, R. Sijmons, C. Cornelisse, H. Morreau and R. Fodde, Familial endometrial cancer in female carriers of MSH6 germline mutations, *Nature Genetics* **23** (1999), 142–144.

[43] Y. Wu, M.J.W. Berends, R.G.J. Mensink, C. Kempinga, R.H. Sijmons, A.G.J. van der Zee, H. Hollema, J.H. Kleibeuker, C.H.C.M. Buys and R.M.W. Hofstra, Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations, *American Journal of Human Genetics* **65** (1999), 1291–1298.

[44] Y. Wu, M.J.W. Berends, J.G. Post, R.G.J. Mensink, E. Verlind, T. van der Sluis, C. Kempinga, R.H. Sijmons, A.G.J. van der Zee, H. Hollema, J.H. Kleibeuker, C.H.C.M. Buys and R.M.W. Hofstra, Germline mutations of EXO1 gene in patients with hereditary nonpolyposis colorectal cancer (HNPCC) and atypical HNPCC forms, *Gastroenterology* **120** (2001), 1580–1587.

[45] Y. Wu, M.J.W. Berends, R.H. Sijmons, R.G.J. Mensink, E. Verlind, K.A. Kooi, T. van der Sluis, C. Kempinga, A.G.J. van der Zee, H. Hollema, C.H.C.M. Buys, J.H. Kleibeuker and R.M.W. Hofstra, A role for MLH3 in hereditary nonpolyposis colorectal cancer, *Nature Genetics* **29** (2001), 137–138.